Entity

Time filter

Source Type

IRVINE, CA, United States

Patent
The Regents Of The University Of California, Immport Therapeutics, Inc. and Yale University | Date: 2013-12-12

Novel immunodominant antigenic proteins and peptides associated with associated with leptospirosis were identified using a proteome array based on expression of ORFs from a


Patent
Immport Therapeutics, Inc. | Date: 2014-10-12

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 2.99M | Year: 2008

DESCRIPTION (provided by applicant): In Phase I of this SBIR, ImmPORT Therapeutics and the UCI Proteomics Core developed a high throughput gene cloning and protein expression platform that allowed the proteomes of any sequenced infectious agent to be expre ssed and printed onto microarray chips. Since Phase I we have cloned and expressed ~15,000 genes from nearly 20 different pathogens associated with biodefense and emerging infectious diseases. By probing the arrays with sera from individuals with well-defi ned clinical stages of infection, we have built up a vast dataset concerning which antibodies are present in different stages of disease. By using statistical and bioinformatic algorithms, we can derive antigen sets that, when combined, can provide the bas is for serological tests able to discriminate between different infections, or even between different stages of the same infection. Phase II, ImmPORT will establish a GMP manufacturing facility and a Clinical Research Lab to offer diagnostic products and s ervices to developers of novel vaccines, physicians and Phama. At the head of a product pipeline will be serodiagnostic immunostrips that will be evaluated for discriminating orthopoxvirus infections from clinically similar rash infections and for diagnosi ng TORCH infections associated with problems during pregnancy. Aim 1: Clone an additional 2000 genes from various rash causing organisms and combine these with an existing inventory of orthopoxvirus and herpes viruses. These will printed on arrays and, in collaboration with colleagues at the CDC, arrays will be probed with well characterized sera to define immunodominant and serodiagnostic antigens. From these data we will produce prototype immunostrips for manufacture and evaluation at CDC. Aim 2: Establis h a GMP protein purification and diagnostic reagent manufacturing facility at ImmPORT. The facility will manufacture protein arrays and immunostrips for its Clinical Research Laboratory , and assay kits that will be sold to biomedical research labs and ref erence laboratories, and as a pivotal FDA-required assay to support licensure of clinical products. Aim 3. Establish a Clinical Research Laboratory at ImmPORT to offer serodiagnostic testing services that will operate in compliance with the Clinical Labora tory Improvement Amendment (CLIA) to be certified to perform validated testing on human specimens for diagnosis, and to provide FDA compliant test results to support licensure of clinical products. With the establishment of a manufacturing infrastructure a t ImmPORT, the company's high throughput antigen discovery platform will continue to rapidly identify candidate antigens for development of other serodiagnostics and subunit vaccine products for category A, B and C biological agents and well as other emerg ing infectious diseases of importance to human health. Project Narrative With support from a phase I SBIR, ImmPORT Therapeutics and the Proteomics Core Lab UCI developed a method for screening the whole proteomes of infectious organisms for diagnostic and vaccine antigens. In Phase II, ImmPORT will establish a GMP manufacturing facility and a Clinical Research Lab to offer diagnostic products and services to developers of novel vaccines, physicians and Phama. At the head of a product pipeline will be serodi agnostic immunostrips that will be evaluated for discriminating orthopoxvirus infections from clinically similar rash infections and for diagnosing TORCH infections associated with problems during pregnancy. PUBLIC HEALTH RELEVANCE With support from a phas e I SBIR, ImmPORT Therapeutics and the Proteomics Core Lab UCI developed a method for screening the whole proteomes of infectious organisms for diagnostic and vaccine antigens. In Phase II, ImmPORT will establish a GMP manufacturing facility and a Clinical Research Lab to offer diagnostic products and services to developers of novel vaccines, physicians and Phama. At the head of a product pipeline will be ser


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

DESCRIPTION (provided by applicant): HIV-1 causes the largest number of deaths from a single infectious agent in the world today. Despite considerable advances in treatment of HIV-1 infection and AIDS, which it causes, there is an urgent need for better methods of prevention and treatment of HIV-1 infection. The development of a safe and effective vaccine to prevent HIV-1 infection or the subsequent development of AIDS is therefore of the utmost importance. This effort, however, has been hampered by a lackof understanding of the correlates of protective immunity and a lack of the tools needed to measure effective anti-HIV-1 immune responses. We have developed a Multi-Clade HIV-1 Proteomic Chip (MC-HIV-1 chip) that can be used as a tool to rapidly screen antibody responses to HIV-1 elicited in vivo in response to infection or vaccination. The current version of the MC-HIV-1 chip which is available commercially from Antigen Discovery Incorporated (ADI) expresses over 100 HIV-1 proteins, protein fragments


Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen

Discover hidden collaborations